Prevalence of cardiovascular disease risk factors in Chinese patients with type 2 diabetes mellitus, 2013–2018

References

• Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375(9712):408–418.
   PubMed Web of Science ®Google Scholar
• Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39(3):472–485.
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–1101.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948.
   PubMed Web of Science ®Google Scholar
• Ma R. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 2018;61(6):1249–1260.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fu C, Luan R, et al. The impact of complication on quality of life among diabetic patients in urban China. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29(10):1029–1033.
   PubMedGoogle Scholar
• Solli O, Stavem K, Kristiansen I. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant P, Anker S, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–3087.
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Blum M, Falasinnu T, et al. Diabetes-attributable mortality in the United States from 2003 to 2016 using a multiple-cause-of-death approach. Diabetes Res Clin Pract. 2019;148:169–178.
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251–272.
   PubMed Web of Science ®Google Scholar
• Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013;126(10):925.e11–925.e22.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xiang H, Mao W, et al. Epidemiological survey of chronic vascular complications of type 2 diabetic in-patients in four municipalities. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002;24(5):452–456.
   PubMedGoogle Scholar
• Berry C, Tardif J, Bourassa M. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol. 2007;49(6):631–642.
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• Haffner S, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234.
   PubMed Web of Science ®Google Scholar
• Wang C, Ye D, Xie Z, et al. Assessment of cardiovascular risk factors and their interactions in the risk of coronary heart disease in patients with type 2 diabetes with different weight levels, 2013–2018. DMSO. 2021;14:4253–4262.
   Web of Science ®Google Scholar
• Kershaw CD, Rubin DB. Multiple imputation for nonresponse in surveys. Biometrics. 1989;45(1):345.
   Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Chi Z, Lee E, Lu M, et al. Vascular disease prevalence in diabetic patients in China: standardised comparison with the 14 centres in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(S2):S82–S6.
   PubMed Web of Science ®Google Scholar
• Lee E, Keen H, Bennett P, et al. Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity. Diabetologia. 2001;44(S2):S3–S13.
   PubMed Web of Science ®Google Scholar
• Clarke P, Glasziou P, Patel A, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 2010;7(2):e1000236.
   PubMed Web of Science ®Google Scholar
• Woodward M, Patel A, Zoungas S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care. 2011;34(12):2491–2495.
   PubMed Web of Science ®Google Scholar
• Norhammar A, Bodegård J, Nyström T, et al. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013. Diabetologia. 2016;59(8):1692–1701.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fu C, Wang W, et al. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients – a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;8:62.
   PubMed Web of Science ®Google Scholar
• Amuna P, Zotor F. Epidemiological and nutrition transition in developing countries: impact on human health and development. Proc Nutr Soc. 2008;67(1):82–90.
   PubMed Web of Science ®Google Scholar
• Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–212.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Wang W, et al. Lifetime risk for cardiovascular disease in a Chinese population: the Chinese multi-provincial cohort study. Eur J Prev Cardiol. 2015;22(3):380–388.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Wang W, et al. Lifetime risk of stroke in young-aged and middle-aged Chinese population: the Chinese multi-provincial cohort study. J Hypertens. 2016;34(12):2434–2440.
   PubMed Web of Science ®Google Scholar
• Bennett D, Du H, Clarke R, et al. Association of physical activity with risk of major cardiovascular diseases in Chinese men and women. JAMA Cardiol. 2017;2(12):1349–1358.
   PubMed Web of Science ®Google Scholar
• Zhang G, Yu C, Zhou M, et al. Burden of ischaemic heart disease and attributable risk factors in China from 1990 to 2015: findings from the global burden of disease 2015 study. BMC Cardiovasc Disord. 2018;18(1):18.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Reaven P, Emanuele N, Wiitala W, et al. Intensive glucose control in patients with type 2 diabetes – 15-year follow-up. N Engl J Med. 2019;380(23):2215–2224.
   PubMed Web of Science ®Google Scholar
• Gerstein H, Miller M, Byington R, et al. Effects of intensive glucose lowering in type 2 diabetes. New England J Med. 2008;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Zhao M, Cooney M, Klipstein-Grobusch K, et al. Simplifying the audit of risk factor recording and control: a report from an international study in 11 countries. Eur J Prev Cardiolog. 2016;23(11):1202–1210.
   PubMed Web of Science ®Google Scholar
• Gyberg V, De Bacquer D, De Backer G, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational research programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14(1):133.
   PubMed Web of Science ®Google Scholar
• Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004;53(Suppl 3):S39–S47.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case–control study in 13 countries. Circulation. 2014;129(9):999–1008.
   PubMed Web of Science ®Google Scholar
• Mongraw-Chaffin M, Peters S, Huxley R, et al. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1.2 million participants. Lancet Diabetes Endocrinol. 2015;3(6):437–449.
   PubMed Web of Science ®Google Scholar
• Tchernof A, Després J. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404.
   PubMed Web of Science ®Google Scholar
• Elbers J, Giltay E, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol. 2003;58(5):562–571.
   PubMed Web of Science ®Google Scholar
• Koster A, Murphy R, Eiriksdottir G, et al. Fat distribution and mortality: the AGES-Reykjavik study. Obesity. 2015;23(4):893–897.
   PubMed Web of Science ®Google Scholar
• Gunathilake W, Song S, Sridharan S, et al. Cardiovascular and metabolic risk profiles in young and old patients with type 2 diabetes. QJM. 2010;103(11):881–884.
   PubMed Web of Science ®Google Scholar
• Inaraja V, Thuissard I, Andreu-Vazquez C, et al. Lipid profile changes during the menopausal transition. Menopause. 2020;27(7):780–787.
   PubMed Web of Science ®Google Scholar